HIF-2 appears to be involved in keeping the stemness of both neuroblastoma and glioma cells, and, as discussed below, HIF-2α expression in breast cancer is also associated to unfavorable disease, suggesting HIF-2α as a potential treatment target in these tumor forms. Here, EPAS1 is linked to breast carcinoma.